e-Therapeutics on trial
Drug discovery and development specialist e-Therapeutics (ETX:AIM) could sign a milestone and royalty payment-yielding licencing agreement if phase II clinical trial results show that its depression treatment ETS6103 works.The...
29 October 2015
